BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Metabolic dysfunction-associated fatty liver disease
1
Rethinking carnitine palmitoyltransferase-II and liver stem cells in metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma
4/18/2025 7:43:21 AM | Browse: 20 | Download: 34
2
Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation
11/26/2024 7:20:29 AM | Browse: 49 | Download: 198
3
Enhancing the functionality of mesenchymal stem cells: An attractive treatment strategy for metabolic dysfunction-associated steatotic liver disease?
10/25/2024 2:40:46 AM | Browse: 56 | Download: 152
4
Predictive value of serum alanine aminotransferase for fatty liver associated with metabolic dysfunction
7/26/2024 10:33:29 AM | Browse: 79 | Download: 273
5
Exploring non-invasive diagnostics for metabolic dysfunction-associated fatty liver disease
7/24/2024 6:41:09 AM | Browse: 72 | Download: 229
6
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease
6/21/2024 3:14:32 AM | Browse: 81 | Download: 239
7
Screening for metabolic-dysfunction associated fatty liver disease: Time to discard the emperor's clothes of normal liver enzymes?
6/6/2024 5:43:14 AM | Browse: 120 | Download: 372
8
Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
3/21/2024 11:37:41 AM | Browse: 157 | Download: 396
9
Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China
3/14/2024 5:31:16 PM | Browse: 153 | Download: 608
10
Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors
8/22/2023 7:39:26 AM | Browse: 198 | Download: 848
11
Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations
10/18/2022 8:29:59 AM | Browse: 477 | Download: 942
12
Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows
9/9/2022 12:48:14 PM | Browse: 407 | Download: 970
13
Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
2/22/2022 9:25:37 AM | Browse: 565 | Download: 1124
14
Nonalcoholic fatty liver disease shows significant sex dimorphism
2/11/2022 5:55:19 AM | Browse: 454 | Download: 1225
15
De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
12/27/2021 5:24:00 AM | Browse: 523 | Download: 886
16
Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis
7/23/2021 8:10:13 AM | Browse: 554 | Download: 1690
17
Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
5/13/2021 10:05:39 AM | Browse: 527 | Download: 1279
18
COVID-19 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
4/21/2021 5:56:26 AM | Browse: 661 | Download: 1233
19
Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic-Chinese population
12/18/2020 5:58:43 AM | Browse: 704 | Download: 1567
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345